Evidence map›Paper›PMID 36046815›Full record

ArticleFrontiers in pharmacology2022

Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice.

Guanglei Xu, Tao Zou, Lijiao Deng, Guang Yang, Tingting Guo, Yi Wang, Chunxiao Niu, Qianqian Cheng, Xiqin Yang, Jie Dong and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Guanglei XuBeijing Institute of Basic Medical Sciences, Beijing, China.
Tao ZouBeijing Institute of Basic Medical Sciences, Beijing, China.
Lijiao DengBeijing Institute of Basic Medical Sciences, Beijing, China.
Guang YangBeijing Institute of Basic Medical Sciences, Beijing, China.
Tingting GuoBeijing Institute of Basic Medical Sciences, Beijing, China.
Yi WangBeijing Institute of Basic Medical Sciences, Beijing, China.
Chunxiao NiuBeijing Institute of Basic Medical Sciences, Beijing, China.
Qianqian ChengBeijing Institute of Basic Medical Sciences, Beijing, China.
Xiqin YangBeijing Institute of Basic Medical Sciences, Beijing, China.
Jie DongBeijing Institute of Basic Medical Sciences, Beijing, China.
Jiyan ZhangBeijing Institute of Basic Medical Sciences, Beijing, China.
Institute of Basic Medical Sciences of the Chinese Academy of Medical SciencesBeijing Institute of Education · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major depressive disorder (MDD) is a highly prevalent psychiatric disorder. But the treatment of depression remains challenging. Anti-inflammatory treatments frequently produce antidepressant effects. EPO-derived helix-B peptide ARA290 has been reported to retain the anti-inflammatory and tissue-protective functions of EPO without erythropoiesis-stimulating effects. The effects of ARA290 on MDD remain elusive. This study established chronic unpredictable mild stress and chronic social defeat stress mouse models. Daily administration of ARA290 during chronic stress induction in two mouse models ameliorated depression-like behavior, similar to fluoxetine. With marginal effects on peripheral blood hemoglobin and red cells, ARA290 and fluoxetine reversed chronic stress-induced increased frequencies and/or numbers of CD11b

Indexed as

ARA290chronic stressdepressionEPOinflammation

Identifiers

PMID36046815
PMCPMC9421426
OpenAlexW4291512411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.